Tricor 145 mg: mau ʻōlelo no ka hoʻohana ʻana, nā analogues a me nā loiloi, nā kumukūʻai ma nā lāʻau lapaʻau o Lūkia

ʻO Tricor kahi lāʻau lapaʻau hypolipidemic he hopena i ka hopena uricosuric a me antiplatelet. Hoʻemi i ka kolamu koko nui ma 20-25%, koko TG e 40-45% a me ka uricemia e 25%. ʻO Fenofibrate ka mea hana ikaika.

He mau triglycerides hoʻokahe haʻahaʻa a ((i ka liʻiliʻi ʻoi) ka cholesterol. Kōkua e hōʻemi i nā kiko o VLDL, LDL (i kahi haʻahaʻa loa), e hoʻonui i ka ʻike o ka HDL anti-atherogenic. ʻAʻole maopopo i ka ʻaoʻao o ka hana.

Hoʻohana pinepine ʻia ka hopena ma ka pae o TG i ka hoʻōla ʻana o ka lipoprotein enanthate. ʻO ka mea, hoʻowahāwahā ka fenofibrate i ka synthes o nā momona momona, ua hāʻawi i ka hoʻonui i ka nui o nā mea i hōʻila o LDL i loko o ka ate, e hoʻonāukiuki i ka synthesis synthesis.

I ka wā e noiʻi ana i ka lāʻau lapaʻau, ua hōʻike ʻia ka hoʻohana ʻana o Tricor i ka hōʻemi o ka kolamu ma 20-25% a me ka triglycerides e ka 40-55% me ka piʻi o HDL-C e 10-30%. I ka poʻe maʻi me ka hypercholesterolemia, kahi e hōʻemi ʻia ai ke kiʻekiʻe o Chs-LDL e ka 20-35%, ka hoʻohana ʻana o ka fenofibrate i ka hōʻemi i nā kāwili: ʻo ka huina Chs / Chs-HDL, Chs-LDL / Chs-HDL a me apo B / apo AI, kahi hōʻailona o ka hopena atherogen.

I ka wā o ka hoʻohanaʻana i ka lāʻau, hiki i nā nui extravascular i ke kolamu (tendon a me ka tubanthous xanthomas) nui a emi loa a emi ʻole.

ʻO kahi pono hou no ka poʻe me ka hyperuricemia a me ka dyslipidemia ka hopena uricosuric o ka mea hana, ka mea e hoʻohemo ai i ka neʻe o ka uric acid ma kahi o 25%.

Aia kahi manaʻo o ka emi ʻana o ka hoonui platelet i kumu ʻia e ka adenosine diphosphate, epinephrine a me ka arachidonic acid.

Nā hōʻailona no ka hoʻohana ʻana

He aha ka mea e kōkua ai iā Tricor? Wahi a nā ʻōlelo kuhikuhi, ua kuhikuhi ʻia ka lāʻau lapaʻau ma kēia mau hihia.

ʻO ka Hypercholesterolemia a me hypertriglyceridemia i hoʻokaʻawale a hui ʻia paha (dyslipidemia type IIa, IIb, III, IV, V) me ka like ʻole o ka hana lapaʻau lāʻau lapaʻau (hōʻemi ke kaumaha, hoʻonui i ka hana kino), ʻoi aku ka hele ʻana o nā hopena pili i ka dyslipidemia - hypertension arterial a me ka ulaula.
ʻO ka hyperlipoproteinemia lua, i nā mau mea e hoʻomau ai ka hyperlipoproteinemia, ʻoiai ke kūpono pono o ka mālama ʻana i nā maʻi lalo (ma ka laʻana, dyslipidemia ma ka maʻi mellitus).

Hāʻawi ʻia ka lāʻau lapaʻau i hui pū me ka ʻai cholesterol a ma ke ʻano he paʻakikī paʻakikī.

Nā palapala ʻōlelo e hoʻohana ai iā Tricor 145 mg, dosage

Lawe ʻia ka papa Tricor 145 mg ma ke alo, me ka ʻole o ka ʻai (piha), holoi ʻia me ka wai maʻemaʻe. ʻO ka lāʻau lapaʻau i loko o kahi inika o 160 mg ke lawe ʻia me ka meaʻai.

ʻO ke ʻano kaulike maʻamau, e like me nā kauoha no ka hoʻohana ʻana, ʻo ia ka 1 papa o Tricor 145 mg 1 manawa i kēlā me kēia lā. Hāʻawi ʻia ka lāʻau lapaʻau no ka wā lōʻihi, ʻoiai eʻai ana.

Hoʻonohonoho ʻia nā pilikia no nā keiki e ke kauka, kau ʻia ka maʻi maʻamau ma muli o ke koʻikoʻi o ke kino o ke keiki - 5 mg / kg i kēlā me kēia lā.

ʻO nā maʻi e lawe ana i 1 papa o Fenofibrate 160 mg 1 manawa i kēlā me kēia lā hiki ke hoʻololi i ka lawe ʻana i ka TRICOR 145 mg me ka hoʻoponopono hou ʻole.

ʻAʻole pono nā poʻe ʻelemakule i ka hoʻoponopono hoʻoponopono ʻia. Me ka nele o ka renal, ua kau ʻia ke ʻano hōʻemi.

Nā ʻōlelo kikoʻī

Ma ka loaʻa ʻole o kahi hopena kūpono, ma hope o 3-6 mau mahina o ka lawe ʻana i ka lāʻau lapaʻau, concomitant a i ʻole kekahi ʻano lapaʻau e hiki ke kuhikuhi ʻia.

Manaʻo ʻia e nānā i ka hana o ka "hepatic" transaminases i kēlā me kēia 3 mau mahina ma ka makahiki mua o ka papa lapaʻau, ka manawa hoʻomaha iki i ka hoʻōho inā hoʻonui ʻia kā lākou hana, a me ka wehe ʻana o nā lāʻau hepatotoxic mai ka mālama like ʻana.

I ka poʻe me ka hyperlipidemia e mālama ʻia ana me ka lālani estrogen a i ʻole ke lawe ʻana i ka contraceptives hormonal waha, e komo pū ana me ka estrogens, ka kumu mua a ʻelua paha ke kūkulu ʻia ʻana o ka hyperlipidemia e hoʻoholo, no ka mea, he hiki ke hoʻonui ʻia ka pae lipid ma muli o ka hoʻokomo o ka estrogens.

Nā hopena hopena

Hoʻomaopopo ka ʻōlelo aʻo i ka hiki ke hoʻomohala i nā hopena ʻaoʻao aʻe i ka wā i kuhikuhi ai iā Tricor:

Lymphatic / circulatory system: loaʻa ʻole - ka hoʻonui nui ʻana i nā ʻōnaehana o ke koko keʻokeʻo a me ka hemoglobin,
Pūnaehana Digestive: pinepine - ʻeha o ka ʻōpū, ka luaʻi, ka lua, ka lemulewa a me ke ʻano hōʻeha, a i kekahi manawa - nā hihia o ka pancreatitis,
ʻO ka ʻōnaehana musculoskeletal a me ka hoʻopili hoʻohui: ʻaʻole luhi - myositis, hoʻokaʻawale i ka myalgia, nāwaliwali, nā ʻōpū ʻana o nā ʻiʻo, ākea loa - rhabdomyolysis,
Hōʻeu: pinepine - ke hoʻonui ʻana i ka hoʻonaninani ʻana i nā transaminases serum, i kekahi manawa - ke hoʻokumu ʻana o nā gallstones, aneane loa - ʻehā o ka hepatitis (i nā ke ʻano o nā hōʻailona - jaundice, hōʻeha - koi ʻia nā hoʻokolohua laboratorium, i nā hihia ke hōʻoia o ka hōʻike ʻana, ua hoʻopau ʻia ka lāʻau).
Pūnaehana wahī: jarang - ʻeha, ka hōʻolo, a me ke ʻano.
Pūnaehana Cardiovascular: i kekahi manawa - thromboembolism venous (hohonu i loko o ka pua thrombosis, pulmonary embolism),
ʻO ka ʻili a me ka momona o ka subcutaneous: i kekahi manawa - ka hana hōʻeha, ka wikiwiki, ka hoʻonaninani photosensitivity, urticaria, ʻike pinepine - alopecia, ʻaʻole loa - kiʻi kiʻi aku i nā erythema, ka hoʻokumu ʻana i nā nodules a i nā blisters paha i loko o nā wahi o ka ʻili i ʻike ʻia e ka UV hihiu kūlohelohe a me ka lā (i i nā hihia pilikino - ma hope o ka hoʻohana mau ʻana me ka ʻole e hoʻomohala ʻana i kekahi ʻōlima).
Ka ea: ākea loa - pneumopathy interstitial,
Nā noiʻi Laboratory: i kekahi manawa - hoʻonui i nā pae o ka urea a me ka mea hana i loko o ka serum.

Nā Hoʻohui

Hoʻohui ʻia ia e kuhikuhi iā Tricor i kēia mau pilikia aʻe:

ʻO ka maʻi ʻeha o ka naʻau, i hele pū ʻia e ka hana o nā mea maʻi lēwa,
ʻO ka hana hema ʻole
ʻOi aku ka hopena o ka pilikia.
ʻO ka ʻeha a me ka pancreitis maʻi kaulike,
ʻO nā maʻi o ka pīpī me ka hypofunction,
ʻLelo ʻia a me ka lactation,
Ke lalo o 18 mau makahiki
ʻO ka hypersensitivity pilikino i nā mea o ka lāʻau.

Ua kuhikuhi ʻia me ka makaʻala i ka poʻe me ka maʻi hepatic a / a i ʻole ke kaulike, no ka hypothyroidism, nā mea maʻi e hōʻino maikaʻi aku i ka waiʻona, nā mea maʻi maʻi, me ka mōʻaukala o nā maʻi ʻōiwi, aʻo ka lawe ʻana i nā anticoagulants waha, HMG-CoA reductase inhibitors.

Ke keu

ʻAʻole wehewehe ʻia nā hōʻailona overdose i nā ʻōlelo kuhikuhi. ʻAʻole kēia mau ʻikepili no nā maʻi lapaʻau ma kahi overdose o ka lāʻau.

ʻAʻole maopopo ka antidote. Hāʻawi ka ʻona. ʻAʻole maikaʻi kēlā Hemodialysis.

Nā manaʻo o Tricor, ke kumukūʻai ma nā lāʻau lapaʻau

Inā pono, hiki iā ʻoe ke hoʻololi i ka Tricor me ka hoʻohui o ka mea ikaika - he mau lāʻau lapaʻau kēia:

Canon Fenofibrate (mai ka 320.90 rubles),
Lipantil (mai 845.00 ʻōpala),
Lipantil 200 M (mai 868.80 mau rubles).

Kūlike ma ka hana:

Ke koho ʻana i nā mea kikoʻī, pono ia e hoʻomaopopo i ka ʻōlelo aʻo no ka hoʻohana ʻana iā Tricor 145 mg, kumu a me nā loiloi e pili ʻole i nā lāʻau lapaʻau o ka hopena like. He mea nui ia e kamaʻilio pū me ke kauka kauka a ʻaʻole hoʻi e hana i kahi loli kūʻokoʻa kūʻokoʻa.

Kumukūʻai ma loko o nā lāʻau lapaʻau ma Moscow a me Lūkia: Tricor 145 mg 30 papa - mai 864 a 999 rubles, e like me 729 mau lāʻau lapaʻau.

E mālama i kahi ma kahi maloʻo a hiki i 25 ° C. Mai mālama i nā keiki. ʻO 3 mau makahiki kahi ola i nā pale.

ʻO nā kūlana o ka hāʻawi ʻana mai i nā lāʻau lapaʻau ma o ke kau ʻana.

3 mau loiloi no "Tricor 145 mg"

ʻAʻole kūpono ʻo Tricor 145 iaʻu, ma hope o ka lawe ʻana iā ia i ʻelua mau mahina, ua ʻeha ka ʻeha i ka paresis o ke kino, nā ʻōpū māhina nui nui (ua loaʻa iaʻu kahi maʻi hemorrhagic 8 mau makahiki i hala, ua hoʻomau ka noho ʻana o ka paresis pololei i kēia manawa) ʻAʻohe hoʻomaikaʻi ʻia ʻana, ʻike wale nō ka nāwaliwali weliweli i loko o ke kino holoʻokoʻa. lethargy.

ʻIke ʻia ka hopena o ka lāʻau lapaʻau. ʻO kekahi hōʻeha ma ke kino holoʻokoʻa. I ka pau ʻana o ka hoʻokipa ʻana, pau nā mea a pau. ʻO ka hopena o ia, me ke kōkua o Tricorr, pono wau e hoʻokō - ua loaʻa. Hoʻopau hou ʻia ka hoʻi ʻana o ka hemophthalmus (hemorrhage intraocular)

ʻAʻole au i hōʻole i ka hilinaʻi i kēia mau palaki - i ka wā hoʻokele, ʻike ʻia ka ʻeha.

E hoʻokuʻu i ke ʻano a me ka ʻano

Loaʻa i Tricor ma loko o nā palapala kiʻi aʻe:

nā papa hana ʻoniʻoni, 145 mg: oblong, keʻokeʻo, me ka pā ʻana o ka hui ma kekahi ʻaoʻao o ka pākaukau a me ka huaʻōlelo "145" ma kekahi (10 mau p. i nā blisters, a i nā pahu pahu 1, 2, 3, 5, 9 a i ʻole 10 nā pōpō, 14 mau pcs i nā pōpō, i ka pahu pahu pahu 2, 6 a i ʻole 7 mau kaʻa, no nā haukapila - 10 mau pcs i loko o nā pahu, i kahi pahu pahu pepa 28 a 30 mau blisters).
nā papa hana ʻoniʻoni, 160 mg: oblong, keʻokeʻo, me ka logo ʻoihana ʻoihana ma ka ʻaoʻao o ka papa a me ka palapala he "160" ma kekahi (10 mau polu i nā blisters, ma ka pahu pahu pahu 1, 2, 3, 4, 5, 9 a i ʻole he 10 kīwaha, 14 mau pcs i nā pōmeni, i ka pahu kīwila 2, 6 a i ʻole 7 mau laka).

Aia pū i kēlā me kēia pū ka pahuhopu no ka hoʻohana ʻana o Tricor.

Hoʻohui i kēlā me kēia papa pālani kiʻi ʻia:

mea hoʻonaʻauao: fenofibrate (micronized i ke ʻano o nanoparticles) - 145 mg a 160 mg,
ʻO nā mea kōkua: sodium lauryl sulfate, sodium stearyl fumarate, crospovidone, colloidal silicon dioxide, docusate sodium, sucrose, lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium stearate, povidone,
sheath film: Opadry OY-B-28920 (titanium dioxide, talc, xanthan gum, polyvinyl alkohol, soy lecithin).

Lapaʻau lāʻau

ʻO Fenofibrate e pili ana i nā makana o ka waikawa fibroic. Hoʻopili ʻia nā hana o kāna hana me ka hana o RAPP-alpha (alpha receptors i hoʻihoʻi ʻia e peroxisome proliferators). Ma muli o ka hoʻihoʻi ʻana o RAPP-alpha, hoʻonui ʻia ka lipolysis o ka lipoproteins atherogenic a ua wikiwiki ʻia kā lākou kiʻi ʻana mai plasma. Ke alakaʻi aku nei kēia i ka hoʻonuiʻana i ke kāpili o nā apoproteins A-1 a me A-2 (Apo A-1 a me Apo A-2). Ma muli o kēia hana, hoʻonui ʻia ke kikoʻī o ka hapa o LDL (lipoproteins haʻahaʻa haʻahaʻa) a me VLDL (lipoproteins haʻahaʻa haʻahaʻa) a hoʻemi ʻia nā kiko o ka hapa HDL (kiʻekiʻe density lipoprotein). Hoʻonui ka Fenofibrate i ka nui o ka hoʻopuka LDL a hoʻohaʻahaʻa i nā kiko o nā pālapa liʻiliʻi a mākeke o LDL, he nui o ka helu o ka nānā i nā poʻe maʻi me kahi phenotype lipid atherogen (ʻoi aku pinepine, loaʻa nā ʻano like ʻole i ka poʻe me ka hopena o ka maʻi naʻau coronary).

I ka hopena o nā noiʻi haumania, hōʻike ʻia ka hoʻoneʻe ʻana o ka fenofibrate i ka hoʻokaʻina o ka triglycerides e ka 40-55% a me ka huina o ka kolamu ma 20-25% me ka piʻi o ka cholesterol a me HDL e ka 10-30%. I ka poʻe maʻi me ka hypercholesterolemia me ka hoʻohaʻahaʻa i ka cholesterol a me LDL (e ka 20-35%) i ka wā e hoʻohana ai i ka fenofibrate, ua hōʻemi ʻia nā ʻano o nā pākuʻi penei: "LDL-cholesterol / HDL-cholesterol", "total cholesterol / HDL-cholesterol", "Apo B / Apo A-1 "(nā helu hoʻohālikelike i kau inoa ʻia nā māka o ka hopena atherogenic).

No ka mea e pili nui ana ʻo Tricor i ka pae o ka triglycerides a me ka LDL cholesterol, kona hoʻohana ʻana ma ka hypercholesterolemia, i hui pū ʻia a ʻaʻole i hele pū ʻia e hypertriglyceridemia (me ka hyperlipoproteinemia kūlohelohe, no ka laʻana, ka type 2 diabetes mellitus), ua hōʻoia maikaʻi ʻia.

I ka wā o ka hoʻohana ʻana o ka fenofibrate, ka nui o ka hoʻohaʻahaʻa a hiki i ka nalowale hoʻopau ʻana i ka nui o nā waiho i ke kolamu o ka kolamu (tuberous a me tendon xanthomas) hiki. I nā kānaka me kahi kiʻekiʻe o ka fibrinogen, kahi nui o ka hoʻohaʻahaʻa nui i kēia mākaukau i ʻike ʻia ma lalo o ka mana o ka fenofibrate (e like me nā mea maʻi me ka piʻi nui o lipoproteins). ʻO ke kiʻekiʻe o kahi mea hōʻailona o ka mumū, ʻo ka protein C-reactive, i hōʻemi ʻia me ka ʻomo fenofibrate.

Ma waena o nā mea ʻē aʻe, hoʻopuka ʻo Tricor i ka hopena uricosuric a hōʻemi i ka hoʻoemi ʻana i ka waikawa uric e pili ana i 25%, ʻo ia ka mea e pono ai ka poʻe hou me ka hyperuricemia a me ka dyslipidemia.

I nā hoʻokolohua holoholona, me ka hoʻāʻo ʻana i ka lāʻau lapaʻau o ka lāʻau, hōʻike ʻia ia e hōʻemi ana i ka platelet aggregation i kumu ʻia e ka epinephrine, ka waikawa arachidonic a me ka adenosine diphosphate.

Lapaʻau lāʻau

ʻO nā papa Tricor i loko o kahi kinona o 160 mg ka loaʻa ʻana o ka bioavailability kiʻekiʻe aʻe ma mua o nā ʻano hana hoʻohālikelike o ka fenofibrate.

Loaʻa ka ʻōpala plasma nui loa ma hope o nā hola 2-4 (145 mg papa) a i ʻole 4-5 mau hola (160 mau papa). ʻAʻole ia e hilinaʻi ma ka kaʻai ʻana o ka meaʻai a me ka hoʻohana mau ʻana i ka lāʻau hoʻomau e kū ʻole i nā ʻano o nā mea maʻi.

Ma hope o ka lawe ʻana iā Tricor, ʻaʻole i ʻike ʻia ka fenofibrate mua i ka plasma koko. Kāhā ʻia ia e ka hydrolysis e nā esterases. ʻO ka mea nui o ka metabolite plasma o ka lāʻau ka hopena o ka acid fenofibroic, ʻoi aku ma mua o 99% i hoʻopaʻaʻia i nā protein plasma (albumin). ʻAʻole i komo ʻo Fenofibrate i ka hana mīhoomika a ʻaʻole ia kahi substrate no ka enzyme CYP3A4.

ʻO ka hapalua hapalua he 20 mau hola. ʻO ke ala nui o ka excretion me ka urine (ma ke ʻano o kahi conjugate o glucuronide a me ka fenofibroic acid). Hiki ke hoʻopau loa ʻia ʻO Fenofibrate i loko o 6 mau lā. I nā poʻe ʻelemakule, ʻaʻole e loli ka nui o ka hoʻopiha ʻana i ka waila fenofibroic.

ʻAʻole mālama ʻia ka hopena kumulative ma hope o hoʻokahi pāmaha ʻeka o ka lāʻau, a ma muli o ka hoʻohana mau ʻana. ʻO ka Hemodialysis no ka wehe ʻana o ka fenofibrate he mea kūpono ʻole (ma muli o ka palena kiʻekiʻe i nā protein plasma).

Nā Hoʻohui

pale ʻole i kekahi pilikia ʻole,
hōʻike hōʻike o ka mōʻaukala o ka maʻi gallbladder,
ka nui o ka pūpū (me ka hoʻomau ʻana o ka hepatitis mau ʻole o ka kumu ʻike kumu a me ka cirrhosis biliary),
ʻo ka maʻi pancreatitis aʻeha paha, koe i nā hihia o ka pancreatitis ma muli o ka hypertriglyceridemia kino,
ka mōʻaukala huakaʻi paʻa, soya lecithin, peanuts a i ʻole nā mea e pili ana i ka anamnesis (ma muli o ka loaʻa o ka maʻi hypersensitivity),
lactase enzyme kakō, galactosemia congenital, malabsorption o galactose a me ka glucose (ʻoiai nā papa i pili ka lactose),
isomaltase / sucrase enzyme deficiency, congenital fructosemia (mai ka sucrose o ʻāpana o nā papa).
ka mōʻaukala phototoxicity a i ʻole photosensitization i ka mālama ʻana i ka ketoprofen a i nā fibrates,
lactation
na keiki a me na opio malalo o na makahiki 18
hypersensitivity i ka fenofibrate, a me nā mea ʻē aʻe o ka lāʻau lapaʻau.

Hoʻohana (Tricor hoʻohana me ka mālama aka):

hypothyroidism
kaumaha o ka hanana ʻana o nā maʻi mōʻī manuʻa,
ka hoʻomohala hui a hydroxymethylglutaryl coenzyme A reductase inhibitors (HMG-CoA reductase) a i ʻole nā anticoagulants waha,
inu waiʻawa
elemakule
ka manawa hāpai ʻana.

Tricor: nā ʻōkuhi no ka hoʻohana (ka ʻana a me nā ʻano)

Pono e kiʻi i ka Tricor ma ke ʻano, me ke ʻano o ka manawa ʻaina. E hoʻopau ʻia ka papa papaʻa ʻole me ka ʻōlohelohe ʻana, holoi ʻia me ka wai o ka wai.

Pono ia e hoʻomau i ka hoʻopiʻi i kahi meaʻai hypocholesterolemic kūikawā, i kuhikuhi ʻia ma mua o ka hoʻomaka ʻana i ka mālama ʻana me ka lāʻau lapaʻau.

ʻO ka papa i ʻōlelo ʻia e hoʻokahi papa (145 mg a 160 mg) hoʻokahi i ka lā. ʻO nā mea maʻi i lawe mua i ka fenofibrate i 200 mg capsules a 160 mg tablet, hoʻokahi capsule a i hoʻokahi papa manawa hoʻokahi i ka lā, hiki ke hoʻololi i kahi papa o Traicor 145 mg a 160 mg ʻole me ka hoʻoponopono hou aʻe.

No nā poʻe ʻelemakule (me ka hana maʻamau maʻamau), hāʻawi ʻia ka lāʻau lapaʻau i nā ʻano maʻamau.

Pono ke loiloi o ka mālama ʻia e ka neʻe ʻana o ka triglycerides, cholesterol a me LDL i ka serum.Inā ma hope o he mau mahina o ka lapaʻau (ma hope o ʻekolu mau mahina) ʻaʻohe hopena, pono ia e hoʻoholo i kahi kūpono o ka mālamaʻana a kuhikuhi i ka concomitant a i ʻole nā lāʻau lapaʻau hou.

Nā hopena hopena

Loaʻa ʻia nā hopena ʻaoʻao o Traicor i ka wā i hoʻopaʻa ʻia e ka ʻimi ʻana i ka pletebo:

pānaʻi a me ke ʻōpala, pinepine a - nā hōʻailona a me nā hōʻailona o ka hōʻeha o ka gastrointestinal (ka luaʻi, ka lua, ke ʻeha o ka ʻōpū, ka lemulewa, ka ʻeha ʻana), ka nui o nā transaminases, nā maʻi pinepine - cholelithiasis, pancreatitis, maʻa - hepatitis,
cardiovascular system: pinepine - i ka hohonu o ka vekōkōlani o ka lalo o ka lalo, i ka thromboembolism pulmonary,
ʻōnaehana o ka hanana: pinepine - ʻeha, lohi - hoʻonaninani, hoʻonui ʻia ka momona,
musculoskeletal system: pinepine - hoʻopōʻino i ka ʻeha (myositis, nāwaliwali o ka naʻau, hū aku i ka myalgia, ʻāwīwī o ka naʻau),
ʻōnaehana hanana: pinepine - hemahema,
lymphatic lula a me ke koko: nā liʻiliʻi - i ka emi o ka pae hemoglobin, e hoʻemi ana i ka nui o nā keʻena koko keʻokeʻo,
ka hiʻi kino: jarang - hypersensitivity,
ka ʻili a me ka momona subcutaneous: pinepine - pinepine, wikiwiki, urticaria, jarang - photosensitivity, palu lauoho lauoho,
nā hoʻokolohua laboratory: pinepine - he hoʻonui i ka likum serum, ʻaʻole liʻiliʻi - hoʻonui i ke kaila o ka urea nitrogen urea.

ʻO nā hopena ʻino o Traicor i hoʻopaʻa ʻia i ka wā o ka hoʻohana ʻana i ka kūʻai aku:

akea a me ka lolo biliary: nā koi o ka cholelithiasis (cholangitis, cholecystitis, colic biliary), jaundice,
pūnaehana hanu: interstitial lung disease,
musculoskeletal ʻōnaehana: rhabdomyolysis,
ka ʻili a me ke momona o ka subcutaneous: hopena kino kino (kūlohelohe neipolysis epidermal, erythema multiforme).

Nā ʻōlelo kikoʻī

Ma mua o ka hoʻomaka i fenofibrate, pono e mālama i ka mālama kūpono e hoʻopau i ke kumu o ka hypercholesterolemia kūloko i nā maʻi e like me ka hypothyroidism, dysproteinemia, me ke ʻano kīpopeke kīnā 2 mellitus, nephrotic syndrome, maʻi ʻeha āpau, a me ka waiʻona a me nā hopena o ka lāʻau lapaʻau.

I ka poʻe maʻi me ka hyperlipidemia, e lawe ana i ka ʻona o ka estrogen, a me ka estrogens, he piʻi ʻana o nā pae lipid ma muli o ka hoʻokomo ʻana o ka estrogen, no laila, pono mua e hoʻoholo i ke ʻano o ka hyperlipidemia (ma mua a i ʻole ke koʻikoʻi).

I ka makahiki mua i kēlā me kēia 3 mau mahina a me ka manawa no ka hoʻōla hou ʻana ua ʻia e nānā i ke ana o ka nui o nā huina o nā ate. I ka hihia o ka hoʻonui i ka hana o nā transaminases ma mua o 3 mau manawa e hoʻohālikelike ʻia me VGN (ka palena o ka maʻamau o ke ʻano maʻamau), pono e hoʻokuʻi ʻia ka lawelawe ʻo Tricor. No nā maʻi hepatitis, pono e hana ʻia nā hoʻokolohua kūpono i kahi hana a, inā hōʻoia ʻia ka maʻi, kāpae i ka lāʻau.

ʻO kekahi o nā hopena o ka fenofibrate ʻo ka hoʻomohala ʻana i ka pancreatitis, nā kumu hiki ke hoʻopili pololei ʻia ʻana i ka Tricor, ka lawa ʻole o ka lāʻau lapaʻau i nā mea maʻi me ka hypertriglyceridemia koʻikoʻi, nā hopena lua (ka sediment a i ka hōʻea ʻana o nā pōhaku i nā kaile bile, e hana ana i ka auhau o ka wai maʻamau).

Hoʻonui ʻia ka mea i loaʻa i ka rhabdomyolysis i ka wā mālama i nā mea maʻi i nā mea maʻi me ka mōʻaukala o ka hana ʻole a i ʻole hypoalbuminemia. Ke hōʻike ʻia nei nā hōʻailona o nā hopena o nā mea laʻala ma ka ʻōpū o ka kalamo (myositis, hoʻokaʻawale i ka myalgia, ka umauma, nā ʻōpū puʻupaʻa, he nui i nā pae o ka creatine phosphokinase ma mua o 5 mau manawa e hoʻohālikelike ʻia me VGN), pono e hoʻōki ka lāʻau fenofibrate.

ʻO ka hoʻokahuli like ʻana o Tricor me nā fibrates a i ʻole ko HMG-CoA reductase inhibitors e hoʻonui i ka hopena o ka hopena ʻalopona ma luna o nā ʻuhane, ʻoi aku ka mea i loaʻa i ka maʻi maʻi ʻeha ma mua o ka mālama ʻana. No kēia kumu, ʻae ʻia ka hoʻohana ʻana o ka lāʻau lapaʻau me nā statins e loaʻa wale i ka ʻōpala i hoʻopiʻi ʻia i loko o ka maʻi ʻōlapa a me ka nui o ka hoʻoulu ʻia ʻana o nā maʻi hōʻeha o ka maʻi maʻi ma nā moʻolelo o nā maʻi o ka ʻiʻo, a ma lalo o ka mākaʻikaʻi kokoke e kuhikuhi ʻia i ke ala mua o nā hōʻailona o ka hōʻino o ka ʻalopona hōʻā.

Inā i ka manawa o ka mālama ʻana e piʻi aʻe ka naʻau o ka creatinine ma mua o 50% mai VGN, pono e hoʻōki ke alakaʻi ʻana o Tricor. Kuhi ʻia ka waiwai cleince kumu kia mālama ʻia ma nā manawa 3 mua, a me ka wā maʻamau i ka wā o ka mālama hou ʻana.

ʻŌpū a me ka lactation

ʻAʻole lawa i ka ʻikepili ma ka hoʻohana ʻana i ka lāʻau lapaʻau i nā wahine hāpai. Ma nā hoʻokolohua i hana ʻia ma nā holoholona, ʻaʻohe mau maka he teratogenic. Ua hoʻomaopopo ʻia ka Embryotoxicity me ka hoʻohana ʻana i ka fenofibrate i ka wā preclinical trial o nā hewa i nā mea momona o ke kino o ka wahine. Hiki i ka hoʻohana ʻana o Tricor i ka wā hāpai ʻana ma hope o ka loiloi ʻana i ka māhele o ka pono i ka makuahine / pilikia i ka maʻi wahine.

ʻAʻole lawa ka ʻike i ka komo ʻana o ka fenofibrate a i ʻole nā metabolites i ka waiū umauma, no laila ʻaʻole kūpono ka hoʻohana ʻana i ka lāʻau lapaʻau i ka wā lactation.

Hoʻohui nūhou

Pono e hui pū me Tricor me ka mālama me nā lāʻau a me nā mea e hiki mai ana.

anticoagulants no ka hoʻoponopono waha: fenofibrate e hoʻomaikaʻi i ka hopena therapeutic o nā anticoagulants a hoʻonui i ka hopena o ke kahe (ʻoi ʻia ʻoi i ka hoʻemi ʻana i ka hopena mua o nā anticoagulants e pili ana i kahi hapakolu a ma laila e hoʻonui pinepine i ia mea).
cyclosporine: hiki i ka nui o ka hanu ke hoʻololi ʻia (hoʻololi ʻia) no laila, no laila, i ka poʻe maʻi āpau, pono ia e nānā i nā ʻano o ke keiki,
ʻO ka HMG-CoA reductase inhibitors (statins), nā mea ʻē aʻe: e hoʻonui ana i ka hōʻemi o ka puʻuwai kino hōʻino.
thiazolidinedione derivatives (rosiglitazone, pioglitazone): hiki ke hōʻemi ʻia ka hoʻōla i ka HDL kolamu a hiki i ka mea hiki ke kuhi (ua paipai ʻia e nānā i ka kukū kōloli HDL a kāpae i ka fenofibrate me ka hoʻēmi nui o kēia ma ke ʻano).

ʻO nā analogues o Tricor he Lipantil 200 M, Lipofen SR, Eclip, Trilipix, Lopid, Fenofibrat Canon, etc.

Nā Hōʻike Manaʻo Traicore

Wahi a nā loiloi, hoʻomaikaʻi maikaʻi ʻo Tricor me ka hana nui - hoʻohaʻahaʻa i ka cholesterol a me ka triglycerides. I ka wā o ka mālama ʻana me ka lāʻau lapaʻau, ʻike nā mea maʻi ma ka maʻamau o ke kō koko koko a me LDL a me HDL, hōʻemi i ka ʻeha i nā wāwae, hōʻemi ka momona. Eia nō naʻe, haʻi pinepine ʻia i kā lākou mau leka, nā mea hoʻohana e wehewehe i nā hopena o ka fenofibrate, e like me ka ʻōpū, ka ʻōpū a me ke kaumaha, flatulence, nāwaliwali maʻamau, nā ʻehaʻeha o ka naʻau, ka hilahila, ka molowale, a me ke kaohi ʻana o ke koko. ʻO kekahi hemahema o ka lāʻau lapaʻau, ʻike nā mea maʻi i kona kumukūʻai kiʻekiʻe.